Drugs / Lianxiaxiaopi Granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06696261 | Feb 2025 → Dec 2026 expected | — | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lianxiaxiaopi Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06696261 ↗ |
| Route | Oral | “took orally” NCT06696261 ↗ |